People · Operator
Named in public records as an officer, director or promoter · active 2010–2010 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Achillion Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $50.1M | $1.8B | 2010 |
Mary Kay S. Fenton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mary Kay S. Fenton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David I Scheer | 1 | 4 |
| Robert L. Van Nostrand | 1 | 4 |
| Michael D. Kishbauch | 1 | 2 |
| Nicholas J. Simon | 1 | 2 |
| David P. Wright | 1 | 2 |
| Gary E. Frashier | 1 | 2 |
| Gautam S. Shah | 1 | 1 |
| Joseph S. Truitt | 1 | 1 |
| Elizabeth S. Olek | 1 | 1 |
| Michael E. Grey | 1 | 1 |
| Milind S. Deshpande | 1 | 1 |
| Dennis C. Liotta | 1 | 1 |
| Jason S. Fisherman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.